Special Issue

Chronic Vascular Disease and Personalized Medicine: Unraveling New Horizons

Message from the Guest Editors

Chronic vascular diseases are a clinical medicine problem that consumes a large amount of economic resources and that most affects the quality of life of the patient. In this sense, biological and medical research has advanced to develop new personalized strategies that allow a better approach to the patient. The connection between research and clinical practice is essential to achieve effective and efficient knowledge generation. For this reason, investigations have to understand all the aspects that allow us to know the state of the tissue, the histology, and the systemic repercussions. Tissue engineering therapies are necessary to allow an effective and integrative repair of tissues damaged by these diseases. All this allows the development of personalized medicine. Therefore, the aim of this Special Issue is to allow biological and medical research to play a key role in chronic vascular diseases for a better and personalized therapy for these patients. Prof. Dr. Melchor Alvarez-MonDr. Miguel Angel OrtegaDr. Miguel A Alvarez-Mon

Guest Editors

Prof. Dr. Julia Bujan

Prof. Dr. Melchor Álvarez de Mon

Dr. Miguel Ortega

Dr. Miguel Ángel Alvarez de Mon

Prof. Dr. Jorge Monserrat

Prof. Dr. Natalio García-Honduvilla

Deadline for manuscript submissions

closed (31 July 2022)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/90269

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

